Banca de QUALIFICAÇÃO: JULLIANA DANIELLE NASCIMENTO DE VERAS

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : JULLIANA DANIELLE NASCIMENTO DE VERAS
DATE: 30/05/2023
TIME: 14:00
LOCAL: Sala Virtual - https://meet.google.com/jne-mbtg-eku
TITLE:

VACCINATION AGAINST HEPATITIS B IN CHRONIC KIDNEYS BEFORE OR AFTER HEMODIALYTIC TREATMENT: RANDOMIZED CLINICAL TRIAL

KEY WORDS:

Vaccination, Hepatitis B, Chronic Kidney Failure.

PAGES: 91
BIG AREA: Ciências da Saúde
AREA: Enfermagem
SUMMARY:

Introduction: Chronic Kidney Disease (CKD) is considered a major public health problem in Brazil and worldwide. When the kidneys cannot fulfill their function of eliminating urea and toxic substances through the urine, an intervention called Renal Replacement Therapy (TRS) is necessary, that is, it is a treatment that performs the functions of the kidneys. And one of the most used options to perform this function is hemodialysis, however, it is the procedure that has the highest risk of exposure to the Hepatitis B virus. important goal in the management of end-stage renal disease, and these patients usually show an impaired immune response to the hepatitis B virus vaccine. answer the following guiding question: Is there an increase in the titre of antibodies against Hepatitis B conferred by vaccination before or after hemodialysis? Objective: To evaluate the increase in the titre of antibodies against Hepatitis B conferred by vaccination before or after hemodialysis. Material and method: This is a quantitative research with an experimental, interventional approach, of the randomized clinical trial (RCT) type, carried out with people who undergo hemodialysis treatment in the age group between 18 and 40 years old using the Hepatitis B vaccine. The hypotheses were tested comparing two groups of individuals simultaneously: one that receives the intervention of interest (experimental group) and another that receives the standard therapy to the intervention (control group). The individuals were allocated into groups through randomization, performed by an external researcher, who used the Excel program, using the function "=randombetween(0,1)" in the Google Sheets software. Data were tabulated in the Microsoft Office Excel program and analyzed in the free software R (R version 4.2.2 (2022-10-31 ucrt)). The study was approved by the Research Ethics Committee through a favorable opinion under nº 5.340. 073 under protocol CAAE-55210822.0.0000.5013, as well as by ReBEC, with approval ID RBR-9vvb89s. Results: The study included 25 people with a mean age of 29.88 years (sd ± 6.45), mostly women (52%, n=13), belonging to the brown race (68%, n =17), the pathology hypertension was mostly present (60%, n=15), mean BMI was 23.24, blood type O (44%, n=11), A (36%, n=9) and B (20%, n=5). The experimental group had 12 participants (48%) and 13 people in the control group (52%). Conclusion: All participants achieved antibody titers (≥ 10 mIU/mL), with a mean anti-Hbs IgG of 674.92 mIU/mL (sd ±369.22) after the entire intervention. The Experimental group had a higher mean anti-HBs antibody titre (763.08 mIU/mL) compared to the control group (593.55 mIU/mL).

BANKING MEMBERS:
Externo(a) à Instituição - ALFREDO DIAS DE OLIVEIRA FILHO - UFS
Presidente - 1924449 - EVELINE LUCENA VASCONCELOS
Interno(a) - 2022453 - PATRICIA DE CARVALHO NAGLIATE